AI assistant
NovoCure Ltd — Director's Dealing 2019
May 10, 2019
31949_dirs_2019-05-10_ff88a139-b89c-40fd-abd6-3246a6a2d952.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2019-05-08
Reporting Person: GROENHUYSEN WILHELMUS CM (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-05-08 | Options to Buy Ordinary Shares | $47.56 | A | 36650 | Acquired | 2029-05-08 | Ordinary Shares (36650) | Direct |
| 2019-05-08 | Options to Buy Ordinary Shares | $47.56 | A | 20000 | Acquired | 2029-05-08 | Ordinary Shares (20000) | Direct |
Footnotes
F1: Options to buy 36,650 ordinary shares will fully vest and become exercisable on May 8, 2022 if (i) the closing price of the Company's ordinary shares is at least $59.45 for a period of at least twenty (20) consecutive trading days at any time between May 8, 2021 and May 8, 2022 and (ii) Mr. Groenhuysen has been continuously employed by the Company through May 8, 2022.
F2: Options to buy 20,000 ordinary shares will fully vest and become exercisable on May 8, 2022 if (i) the closing price of the Company's ordinary shares is at least $71.34 for a period of at least twenty (20) consecutive trading days at any time between May 8, 2021 and May 8, 2022 and (ii) Mr. Groenhuysen has been continuously employed by the Company through May 8, 2022.